BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi E, Kim W, Joo SK, Park S, Park JH, Kang YK, Jin SY, Chang MS. Expression patterns of STAT3, ERK and estrogen-receptor α are associated with development and histologic severity of hepatic steatosis: a retrospective study. Diagn Pathol 2018;13:23. [PMID: 29615085 DOI: 10.1186/s13000-018-0698-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiao J, Sanchez JI, Saldarriaga O, Solis LM, Tweardy DJ, Maru DM, Stevenson HL, Beretta L. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100628] [Reference Citation Analysis]
2 Wang Y, Wu C, Zhou J, Fang H, Wang J. Overexpression of estrogen receptor β inhibits cellular functions of human hepatic stellate cells and promotes the anti-fibrosis effect of calycosin via inhibiting STAT3 phosphorylation. BMC Pharmacol Toxicol 2022;23:77. [PMID: 36207725 DOI: 10.1186/s40360-022-00617-y] [Reference Citation Analysis]
3 Lannigan DA. ERK1/2-RSK2 Signaling in Regulation of ERα-Mediated Responses. Endocrinology 2022;163:bqac106. [PMID: 35880639 DOI: 10.1210/endocr/bqac106] [Reference Citation Analysis]
4 Li Y, He XL, Zhou LP, Huang XZ, Li S, Guan S, Li J, Zhang L. Asiatic acid alleviates liver fibrosis via multiple signaling pathways based on integrated network pharmacology and lipidomics. Eur J Pharmacol 2022;931:175193. [PMID: 35963324 DOI: 10.1016/j.ejphar.2022.175193] [Reference Citation Analysis]
5 Hu T, Wei M, Hong G, Qi T, Xiang Y, Yang Y, Yi Y. Xiaoyao San attenuates hepatic steatosis through estrogen receptor α pathway in ovariectomized ApoE-/- mice. J Ethnopharmacol 2022;282:114612. [PMID: 34496266 DOI: 10.1016/j.jep.2021.114612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hung Y, Sritharan R, Vohl M, Ilkayeva O, Biertho L, Tchernof A, White PJ, Sethupathy P. Super-enhancer signature reveals key mechanisms associated with resistance to non-alcoholic steatohepatitis in humans with obesity.. [DOI: 10.1101/2021.08.20.457162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Deng Y, Yuan J, Qiu J, Tang B, Chen X, Hu S, He H, Liu H, Li L, Han C, Hu J, Wang J. Oestrogen promotes lipids transportation through oestrogen receptor α in hepatic steatosis of geese in vitro. J Anim Physiol Anim Nutr (Berl) 2021. [PMID: 34111322 DOI: 10.1111/jpn.13590] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 31.0] [Reference Citation Analysis]
9 Blagotinšek Cokan K, Urlep Ž, Moškon M, Mraz M, Kong XY, Eskild W, Rozman D, Juvan P, Režen T. Common Transcriptional Program of Liver Fibrosis in Mouse Genetic Models and Humans. Int J Mol Sci 2021;22:E832. [PMID: 33467660 DOI: 10.3390/ijms22020832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cokan KB, Urlep Ž, Moškon M, Mraz M, Kong XY, Eskild W, Rozman D, Juvan P, Režen T. Common transcriptional programme of liver fibrosis in mouse genetic models and humans.. [DOI: 10.1101/2020.11.02.364901] [Reference Citation Analysis]
11 Zhang T, Gu J, Guo J, Chen K, Li H, Wang J. Renalase Attenuates Mouse Fatty Liver Ischemia/Reperfusion Injury through Mitigating Oxidative Stress and Mitochondrial Damage via Activating SIRT1. Oxid Med Cell Longev 2019;2019:7534285. [PMID: 31949882 DOI: 10.1155/2019/7534285] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
12 Beck JR, Cabral F, Rasineni K, Casey CA, Harris EN, Stains CI. A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease. Biochemistry 2019;58:3911-7. [PMID: 31433166 DOI: 10.1021/acs.biochem.9b00547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Wei W, Ji S. Cellular senescence: Molecular mechanisms and pathogenicity. J Cell Physiol. 2018;233:9121-9135. [PMID: 30078211 DOI: 10.1002/jcp.26956] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 20.8] [Reference Citation Analysis]
14 Mehrdoost S, Yaghmaei P, Jafary H, Ebrahim-Habibi A. The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease. Iran J Basic Med Sci 2021;24:451-9. [PMID: 34094026 DOI: 10.22038/ijbms.2021.52239.11822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]